Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)

0
Delayed Quote. Delayed London Stock Exchange - 10/22 11:35:17 am
49 GBp   +2.08%
10/14 VERNALIS : Non-Executive Buys 103,000 Shares (DIRECTOR DEALINGS)
10/14 VERNALIS : Transactions of Directors
10/10 VERNALIS : Opens New Office In Pennsylvania, Bolsters US Management Team
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/16/2014 10/17/2014 10/20/2014 10/21/2014 10/22/2014 Date
46.75(c) 47.25(c) 48.25(c) 48(c) 49(c) Last
56 705 2 659 882 448 757 589 505 309 539 Volume
-4.10% +1.07% +2.12% -0.52% +2.08% Change
More quotes
Company
Vernalis Plc is a research and development stage pharmaceutical company.The company provides pharmaceutical products for a range of medical disorders.It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.The group has one marketed product,... 
Surperformance© rating of Vernalis plc
Trading Rating : Investor Rating :
More about the company
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Financials ( GBP)
Sales 2014 10,7 M
EBIT 2014 -11,7 M
Net income 2014 -10,2 M
Finance 2014 30,8 M
Yield 2014 -
Sales 2015 13,8 M
EBIT 2015 -17,0 M
Net income 2015 -15,6 M
Finance 2015 20,2 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 17,0x
EV / Sales 2015 13,9x
Capitalization 212 M
More Financials
Latest news on VERNALIS PLC
10/14 VERNALIS : Non-Executive Buys 103,000 Shares (DIRECTOR DEALINGS)
10/14 VERNALIS : Transactions of Directors
10/10 VERNALIS : Opens New Office In Pennsylvania, Bolsters US Management Team
10/10 VERNALIS : Opens US Office and Strengthens US Team With the Appointment of SVP M..
10/09 VERNALIS : Licenses V2006 To RedoxTherapies For Use In Immuno-oncology
10/09 VERNALIS : Licenses V2006 to RedoxTherapies Inc for Use in Immuno-Oncology
09/24 VERNALIS : FDA accepts Tuzistra™ XR CCP-01 NDA for full review
09/16 VERNALIS : FDA accepts Tuzistra XR (CCP-01) NDA for full review
09/15 VERNALIS : Says Tuzistra Gets US New Drug Application Confirmation
09/15 VERNALIS : *canaccord raises vernalis plc price target to 56 (54) pence - 'buy'
09/15 VERNALIS : FDA accepts TuzistraTM XR NDA for full review
09/15 VERNALIS : Announces FDA Accepts Tuzistra(TM) XR NDA for Full Review
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF